GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

Oncolytics Biotech (TSX:ONC), a clinical-stage oncology immunotherapy stock, is up by more than 20 per cent after onboarding ...

Health secretary Robert F. Kennedy Jr. yesterday appointed a new, smaller vaccine advisory committee at the CDC — just two ...

Behind the veneer of accessibility lies a critical bottleneck in clinical trial readiness, especially pronounced in trials ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

Hyderabad based vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed a potential vaccine candidate for ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...